Pharvaris (PHVS) Common Equity (2019 - 2026)

Pharvaris' Common Equity history runs 8 years deep, the most recent figure standing at $276.7 million for Q1 2026.

• Quarterly Common Equity rose 16.73% year-over-year to $276.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $276.7 million (up 16.73% YoY) and the FY2025 annual result came in at $306.5 million, up 5.76% from the prior year.
• Common Equity was $276.7 million for Q1 2026 at Pharvaris, down from $315.8 million in the prior quarter.
• Across five years, Common Equity topped out at $413.2 million in Q4 2023 and bottomed at $138.6 million in Q1 2023.
• A 5-year average of $260.5 million and a median of $237.0 million in 2025 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2024 — Common Equity surged 181.48% — and 2025, when it sank 41.77%.
• Pharvaris' Common Equity stood at $152.3 million in 2022, then soared by 171.35% to $413.2 million in 2023, then slumped by 30.76% to $286.1 million in 2024, then increased by 10.36% to $315.8 million in 2025, then declined by 12.38% to $276.7 million in 2026.
• Business Quant data shows PHVS's Common Equity at $276.7 million in Q1 2026, $315.8 million in Q4 2025, and $365.0 million in Q3 2025.